1. Scrip

PhRMA's Narasimhan Asks Japan To Reform Pricing Policies

Phase I Waiver Plan 'Very Positive'

 
• By Lisa Takagi

Pointing to what it says is decreased R&D in Japan in contrast to the global market, PhRMA has again urged the country to revise its drug pricing policies and support innovation, while cautiously welcoming new moves to waive a requirement for Phase I trials in the country.

Vassant Narashimhan, Chair of the PhRMA Board of Directors at press conference in Tokyo, Japan
Vasant Narashimhan, Chair of the PhRMA Board of Directors at press conference in Tokyo, Japan • Source: Lisa Takagi

The US innovation-based industry association, Pharmaceutical Research Manufacturers of America (PhRMA), has again called on Japan to reform its unpredictable and frequent reimbursement price-cutting policies for prescription drugs and to direct more funding and support to innovation in the national biopharma industry.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia